Created at Source Raw Value Validated value
June 25, 2024, noon usa

inclusion criteria: 1. healthy women ≥18 years of age who are between 24 0/7 and 34 0/7 weeks' gestation on the day of planned vaccination, with an uncomplicated, singleton pregnancy, who are at no known increased risk for complications. 2. participants who are willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures. 3. healthy participants who are determined by medical history, physical examination, and clinical judgment to be appropriate for inclusion in the study 4. documented negative hiv antibody test (phase 2 only), syphilis test, and hbv surface antigen test during this pregnancy and prior to randomization 5. participant is willing to give informed consent for her infant to participate in the study 6. capable of giving signed informed consent

inclusion criteria: 1. healthy women ≥18 years of age who are between 24 0/7 and 34 0/7 weeks' gestation on the day of planned vaccination, with an uncomplicated, singleton pregnancy, who are at no known increased risk for complications. 2. participants who are willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures. 3. healthy participants who are determined by medical history, physical examination, and clinical judgment to be appropriate for inclusion in the study 4. documented negative hiv antibody test (phase 2 only), syphilis test, and hbv surface antigen test during this pregnancy and prior to randomization 5. participant is willing to give informed consent for her infant to participate in the study 6. capable of giving signed informed consent

Nov. 16, 2021, 6:30 p.m. usa

inclusion criteria: healthy women ≥18 years of age who are between 24 0/7 and 34 0/7 weeks' gestation on the day of planned vaccination, with an uncomplicated, singleton pregnancy, who are at no known increased risk for complications. participants who are willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures. healthy participants who are determined by medical history, physical examination, and clinical judgment to be appropriate for inclusion in the study documented negative hiv antibody test (phase 2 only), syphilis test, and hbv surface antigen test during this pregnancy and prior to randomization participant is willing to give informed consent for her infant to participate in the study capable of giving signed informed consent

inclusion criteria: healthy women ≥18 years of age who are between 24 0/7 and 34 0/7 weeks' gestation on the day of planned vaccination, with an uncomplicated, singleton pregnancy, who are at no known increased risk for complications. participants who are willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures. healthy participants who are determined by medical history, physical examination, and clinical judgment to be appropriate for inclusion in the study documented negative hiv antibody test (phase 2 only), syphilis test, and hbv surface antigen test during this pregnancy and prior to randomization participant is willing to give informed consent for her infant to participate in the study capable of giving signed informed consent

April 16, 2021, 12:31 a.m. usa

inclusion criteria: 1. healthy women ≥18 years of age who are between 24 0/7 and 34 0/7 weeks' gestation on the day of planned vaccination, with an uncomplicated, singleton pregnancy, who are at no known increased risk for complications. 2. participants who are willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures. 3. healthy participants who are determined by medical history, physical examination, and clinical judgment to be appropriate for inclusion in the study 4. documented negative hiv antibody test (phase 2 only), syphilis test, and hbv surface antigen test during this pregnancy and prior to randomization 5. participant is willing to give informed consent for her infant to participate in the study 6. capable of giving signed informed consent

inclusion criteria: 1. healthy women ≥18 years of age who are between 24 0/7 and 34 0/7 weeks' gestation on the day of planned vaccination, with an uncomplicated, singleton pregnancy, who are at no known increased risk for complications. 2. participants who are willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures. 3. healthy participants who are determined by medical history, physical examination, and clinical judgment to be appropriate for inclusion in the study 4. documented negative hiv antibody test (phase 2 only), syphilis test, and hbv surface antigen test during this pregnancy and prior to randomization 5. participant is willing to give informed consent for her infant to participate in the study 6. capable of giving signed informed consent

Feb. 17, 2021, 12:31 a.m. usa

inclusion criteria: 1. healthy women ≥18 years of age who are between 24 0/7 and 34 0/7 weeks' gestation on the day of planned vaccination, with an uncomplicated, singleton pregnancy, who are at no known increased risk for complications. 2. participants who are willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures. 3. healthy participants who are determined by medical history, physical examination, and clinical judgment to be appropriate for inclusion in the study 4. documented negative hiv antibody test, syphilis test, and hbv surface antigen test during this pregnancy and prior to randomization 5. participant is willing to give informed consent for her infant to participate in the study 6. capable of giving signed informed consent

inclusion criteria: 1. healthy women ≥18 years of age who are between 24 0/7 and 34 0/7 weeks' gestation on the day of planned vaccination, with an uncomplicated, singleton pregnancy, who are at no known increased risk for complications. 2. participants who are willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures. 3. healthy participants who are determined by medical history, physical examination, and clinical judgment to be appropriate for inclusion in the study 4. documented negative hiv antibody test, syphilis test, and hbv surface antigen test during this pregnancy and prior to randomization 5. participant is willing to give informed consent for her infant to participate in the study 6. capable of giving signed informed consent